

Supporting Information

A productive isocyanide/ Ag_2CO_3 -promoted addition of heteroatoms to alkynes under mild condition

Jie Lei,^a Jia Xu,^a Ya-Fei Luo,^a Jie Li,^a Jing-Ya Wang,^a Hong-yu Li,^b Zhi-Gang Xu,^{*a} Zhong-Zhu Chen^{*a}

^a College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, China. Email: 18883138277@163.com; xzg@cqwu.edu.cn

^b Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. Email: HLi2@uams.edu

Table of Contents	Page
General Experimental.....	2
Optimization of the reaction condition.....	2
General procedures for condition A.....	2
General procedures for synthesis of B.....	3
General procedures for compounds 20.....	3
General procedures for compounds 21.....	3
Control experiments.....	4
X-ray structure of 8 and 12.....	4
HPLC conversion of yield and time.....	5-8
Density functional theory (DFT) calculations.....	9-11
NMR Characterization Data and Figures of Products.....	12-88

General Experimental

¹H and ¹³C NMR were recorded on a Bruker 400 spectrometer. ¹H NMR data are reported as follows: chemical shift in ppm (δ), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constant (Hz), relative intensity. ¹³C NMR data are reported as follows: chemical shift in ppm (δ). LC/MS analyses were performed on a Shimadzu-2020 LC-MS instrument using the following conditions: Shim-pack VP-ODS C18 column (reverse phase, 150 x 4.6 mm); a linear gradient from 10% water and 90% acetonitrile to 75% acetonitrile and 25% water over 6.0 min; flow rate of 0.5 mL/min; UV photodiode array detection from 200 to 400 nm. High-resolution mass spectra (HRMS) were recorded on Thermo Scientific Exactive Plus System. The products were purified by Biotage IsoleraTM Spektra Systems and hexane/EtOAc solvent systems. All reagents and solvents were obtained from commercial sources and used without further purification.

Table S1 Optimization of the reaction condition.^a

Entry	Solvent	Yield (%) ^b
1	EtOH	93
2	MeCN	91
4	H ₂ O	67
5	Toluene	39
6	THF	<10
7	DMF	74
8	DMSO	55
9	DCM	84
10 ^c	EtOH	91

^a Reaction condition: **1a** (0.3 mmol), 1 mol% Ag₂CO₃, 4 mol% *t*-BuNC, solvent (3.0 mL), room temperature, 30 min. ^b Isolated yield. ^c **1a** (0.3 mmol), 1 mol% Ag₂CO₃, 1.0 equiv. *t*-BuNC, solvent (3.0 mL), room temperature, 30 min.

General procedures for condition A.

To a solution of ethanol (3.0 mL) in flask, substrate (0.3 mmol), *tert*-butyl isocyanide (4 mol%) and silver carbonate (1 mol%) were added at room temperature. And then the reaction mixture was stirred for 30 min. The reaction mixture was monitored by TLC.

When the reaction was completed, the solvent was removed under reduced pressure. Then the reaction mixture was diluted with EtOAc (15.0 mL), washed with sat. Na₂CO₃ and brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford the relative targeted product.

General procedures for condition B.

To a solution of ethanol (3.0 mL) in flask, substrate (0.3 mmol), *tert*-butyl isocyanide (16 mol%) and silver carbonate (3 mol%) were added at room temperature. And then, the reaction mixture was heated to 50 °C and stirred for 1 h. The reaction mixture was monitored by TLC. When the reaction was completed, the solvent was removed under reduced pressure. Then the reaction mixture was diluted with EtOAc (15.0 mL), washed with sat. Na₂CO₃ and brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford the relative targeted product.


General procedure for compound 19

In a solution of compound **2I** (0.2 mmol) in DCE (3.0 mL), BF₃ Et₂O (1.5 equiv) was added and stirred at room temperature for 2 h. When the reaction was completed, the reaction mixture was diluted with EtOAc (15.0 mL), washed with brine. The organic layer was dried over MgSO₄ and concentrated. The residue was purified by silica gel column chromatography using a gradient of ethyl acetate/hexane (0-100%) to afford the targeted product **19** in 73% yield.

General procedure for compound 21


A mixture of **2I** (0.2 mmol) and **20** (0.3 mmol) was added to the solvent of PhCl (2.0 mL) in an oven dried reaction tube. Then ZnI₂ (20 mol%) was added to it and heated with microwave irradiation at 100 °C for 10 min. After the completion of the reaction, the reaction was cooled to room temperature and extracted with dichloromethane. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent under vacuum; it was purified by column chromatography on a silica gel using a gradient of ethyl acetate/hexane (0-100%) to afford the pure product **21** (51%) as a white solid.

Control experiments



Reaction Conditions	Yield % of 2a
1 AgOAc (2 mol%), <i>t</i> -BuNC (8 mol%), EtOH, r.t., 30 min.	N/D
2 AgOAc (2 mol%), <i>t</i> -BuNC (8 mol%), K ₂ CO ₃ (16 mol%), EtOH, r.t., 30 min.	91%
3 K ₂ CO ₃ (16 mol%), EtOH, r.t., 30 min.	N/D
4 [Ag(<i>t</i> -BuNC) ₄]ClO ₄ , EtOH, r.t., 30 min.	N/D
5 [Ag(c-HexNC) ₂]ClO ₄ , EtOH, r.t., 30 min.	N/D
6 Ag ₂ CO ₃ (1 mol%), <i>t</i> -BuNC (4 mol%), TEMPO (2.0 equiv.), EtOH, r.t., 30 min.	87%
7 Ag ₂ CO ₃ (1 mol%), <i>t</i> -BuNC (4 mol%), BHT (2.0 equiv.), EtOH, r.t., 30 min.	89%
8 Ag power (2 mol%), <i>t</i> -BuNC (8 mol%), EtOH, r.t., 30 min.	N/D


X-ray structures of compound 8 and 12



HPLC conversion of yield and time


$t = 5$ min (Ag_2CO_3 and isocyanide were added)

mAU




$t = 6$ min

mAU




$t = 8$ min

mAU




t = 10 min

mAU




t = 15 min

mAU




t = 17 min

mAU




t = 20 min

mAU




t = 24 min

mAU




t = 27 min

mAU




t = 29 min

mAU




t = 30 min

mAU



Density functional theory (DFT) calculations

Optimized structures



Computational details

All calculations were performed using Gaussian 16 program package,^[1] employing the B3LYP-D3(BJ)^[2] density functional with the def2-SVP basis set. Geometries were optimized in toluene solvent and characterized by frequency analysis at 298.15K. Unless specified, the Gibbs free energies obtained at the B3LYP-D3(BJ)/def2-SVP (SMD, toluene) level at 298.15K were used in the discussion. The optimized molecular structures were visualized by CYLview (2.0 version) software.^[3]

- [1] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.
- [2] Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H. A Consistent and Accurate Ab Initio Parametrization of Density Functional Dispersion Correction (DFT-D) for the 94 Elements H-Pu. *J. Chem. Phys.* **2010**, *132* (15), 154104.
- [3] CYLview20; Legault, C. Y., Université de Sherbrooke, 2020
(<http://www.cylview.org>)

Table S2 The ZPE-correct electronic energies (E_{ZPE}), enthalpies (H), and Gibbs free energies (G) for all stationary points (in Hartree), obtained at the B3LYP-D3(BJ)/def2-SVP theoretical level.

Structures	^a ZPE	^b Hc	^c Gc	E_{ZPE}	H	G
A-IM1	0.481562	0.517834	0.402703	-1672.61641	-1672.580139	-1672.695269
A-TS1	0.479467	0.51525	0.401713	-1672.618426	-1672.582642	-1672.69618
A-IM2	0.48193	0.518144	0.4045	-1672.61718	-1672.580966	-1672.694611
A-TS2	0.480922	0.516996	0.391247	-1672.522646	-1672.486573	-1672.612322
A-IM3	0.484819	0.520658	0.406037	-1672.616147	-1672.580308	-1672.694929
A-TS3	0.479787	0.515056	0.40299	-1672.589316	-1672.554046	-1672.666112
A-IM4	0.485134	0.520645	0.408011	-1672.625899	-1672.590388	-1672.703022
B-TS2	0.349284	0.375564	0.280078	-1422.078959	-1422.052679	-1422.148165
B-IM3	0.353078	0.380063	0.288941	-1422.167279	-1422.140294	-1422.231416
B-TS3	0.348384	0.374658	0.286219	-1422.149840	-1422.123566	-1422.212005


^a Zero-point correction energy;

^b Thermal correction to enthalpy;

^c Thermal correction to Gibbs free energy.


NMR Characterization Data and Figures of Products

(Z)-1-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)pyrrolidine




2a, 93%, white solid, mp. = 109-110 °C, (EA/Hex = 10%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.9 Hz, 2H), 7.42 (d, J = 7.4 Hz, 1H), 7.36 (td, J = 7.9, 1.4 Hz, 2H), 7.32 – 7.27 (m, 1H), 7.20 (t, J = 7.4 Hz, 1H), 7.07 – 6.98 (m, 2H), 5.83 (s, 1H), 5.16 (s, 1H), 2.81 – 2.52 (m, 4H), 1.74 (s, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 158.18, 154.71, 135.12, 129.40, 128.47, 128.39, 126.23, 126.09, 125.54, 122.06, 110.16, 105.52, 63.78, 48.07, 23.36. HRMS (ESI) m/z calcd for C₁₉H₂₀NO⁺ (M+H)⁺ 278.1539, found 278.1548.

(Z)-1-(2-(4-methoxybenzylidene)-2,3-dihydrobenzofuran-3-yl)pyrrolidine




2b, 98%, white solid, mp. = 107-108 °C, (EA/Hex = 10%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 7.4 Hz, 1H), 7.28 (dd, J = 11.0, 3.5 Hz, 1H), 7.01 (dd, J = 15.2, 7.7 Hz, 2H), 6.93 – 6.89 (m, 2H), 5.77 (d, J = 1.1 Hz, 1H), 5.13 (s, 1H), 3.82 (s, 3H), 2.75 (dd, J = 9.3, 3.1 Hz, 2H), 2.61 (dd, J = 9.3, 3.1 Hz, 2H), 1.74 (t, J = 6.2 Hz, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 158.24, 158.01, 153.02, 129.69, 129.32, 127.96, 126.09, 125.69, 121.89, 113.83, 110.08, 105.13, 63.69, 55.31, 48.05, 23.33. HRMS (ESI) m/z calcd for C₂₀H₂₂NO₂⁺ (M+H)⁺ 308.1645, found 308.1645.

(Z)-1-(2-(4-(tert-butyl)benzylidene)-2,3-dihydrobenzofuran-3-yl)pyrrolidine




2c, 95%, white solid, mp. = 110-111 °C, (EA/Hex = 5%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, J = 8.4 Hz, 2H), 7.41 (t, J = 7.4 Hz, 3H), 7.32 – 7.24 (m, 1H), 7.01 (dd, J = 14.7, 7.6 Hz, 2H), 5.82 (s, 1H), 5.15 (s, 1H), 2.82 – 2.56 (m, 4H), 1.74 (d, J = 6.1 Hz, 4H), 1.33 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 158.24, 154.14, 149.21, 132.30, 129.35, 128.19, 126.08, 125.69, 125.32, 121.95, 110.12, 105.35, 63.71, 48.02, 34.56, 31.35, 23.34. HRMS (ESI) m/z calcd for C₂₃H₂₈NO⁺ (M+H)⁺ 334.2165, found 334.2169.

(Z)-1-(2-benzylidene-6-methyl-2,3-dihydrobenzofuran-3-yl)pyrrolidine




2d, 98%, white solid, mp. = 106-107 °C, (EA/Hex = 15%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 7.7 Hz, 2H), 7.29 (d, J = 7.5 Hz, 1H), 7.19 (t, J = 7.4 Hz, 1H), 6.88 (s, 1H), 6.83 (d, J = 7.5 Hz, 1H), 5.81 (s, 1H), 5.13 (s, 1H), 2.68 (dd, J = 55.9, 5.7 Hz, 4H), 2.37 (s, 3H), 1.74 (s, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 158.43, 155.26, 135.24, 128.37, 126.15, 125.67, 122.82, 110.80, 105.30, 63.65, 48.04, 23.35, 21.67. HRMS (ESI) m/z calcd for C₂₀H₂₂NO⁺ (M+H)⁺ 292.1696, found 292.1696.

(Z)-1-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)piperidine




2e, 91%, white solid, mp. = 108-109 °C, (EA/Hex = 15%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.8 Hz, 2H), 7.42 (d, J = 7.2 Hz, 1H), 7.37 (t, J = 7.7 Hz, 2H), 7.31 – 7.24 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 7.02 (dd, J = 12.4, 5.0 Hz, 2H), 5.86 (d, J = 1.2 Hz, 1H), 4.97 (s, 1H), 2.69 (dt, J = 10.6, 5.3 Hz, 2H), 2.48 (dt, J = 10.5, 5.2 Hz, 2H), 1.54 (dd, J = 11.1, 5.7 Hz, 4H), 1.40 (dt, J = 11.9, 6.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.24, 154.76, 135.30, 129.28, 128.40, 126.14, 125.32, 122.00, 110.04, 104.94, 68.73, 49.71, 26.50, 24.49. HRMS (ESI) m/z calcd for C₂₀H₂₂NO⁺ (M+H)⁺ 292.1696, found 292.1698.

(Z)-1-(2-benzylidene-5-methyl-2,3-dihydrobenzofuran-3-yl)piperidine




2f, 92%, white solid, mp. = 109-110 °C, (EA/Hex = 10%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.9 Hz, 2H), 7.36 (t, J = 7.6 Hz, 2H), 7.20 (dd, J = 13.9, 6.5 Hz, 2H), 7.06 (d, J = 8.1 Hz, 1H), 6.91 (d, J = 8.1 Hz, 1H), 5.83 (s, 1H), 4.93 (s, 1H), 2.68 (dt, J = 10.4, 5.1 Hz, 2H), 2.55 – 2.44 (m, 2H), 2.35 (s, 3H), 1.61 – 1.51 (m, 4H), 1.40 (t, J = 10.0 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 156.18, 155.11, 135.40, 131.37, 129.72, 128.36, 126.56, 126.02, 125.2, 109.52, 104.67, 68.85, 49.68, 26.49, 24.48, 21.03. HRMS (ESI) m/z calcd for C₂₁H₂₄NO⁺ (M+H)⁺ 306.1852, found 306.1855.

(Z)-1-(5-methyl-2-(4-propylbenzylidene)-2,3-dihydrobenzofuran-3-yl)piperidine




2g, 95%, white solid, mp. = 121-122 °C, (EA/Hex = 10%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, J = 8.1 Hz, 2H), 7.22 (s, 1H), 7.17 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.1 Hz, 1H), 6.90 (d, J = 8.1 Hz, 1H), 5.81 (s, 1H), 4.92 (s, 1H), 2.67 (dt, J = 10.5, 5.1 Hz, 2H), 2.58 (t, J = 7.6 Hz, 2H), 2.47 (dt, J = 10.4, 5.0 Hz, 2H), 2.34 (s, 3H), 1.64 (dd, J = 15.0, 7.5 Hz, 2H), 1.58 – 1.50 (m, 4H), 1.44 – 1.37 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 156.25, 154.32, 140.64, 132.78, 131.25, 129.69, 128.51, 128.27, 126.57, 125.27, 109.50, 104.73, 68.75, 49.62, 37.86, 26.47, 24.63, 24.48, 21.05, 13.89. HRMS (ESI) m/z calcd for C₂₄H₃₀NO⁺ (M+H)⁺ 348.2322, found 348.2329.

(Z)-1-(2-(4-propylbenzylidene)-2,3-dihydrobenzofuran-3-yl)piperidine




2h, 97%, white solid, mp. = 119-120 °C, (EA/Hex = 10%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 7.3 Hz, 1H), 7.30 – 7.22 (m, 1H), 7.18 (d, J = 8.0 Hz, 2H), 7.05 – 6.97 (m, 2H), 5.84 (s, 1H), 4.96 (s, 1H), 2.68 (dt, J = 10.5, 5.2 Hz, 2H), 2.59 (t, J = 7.6 Hz, 2H), 2.47 (dt, J = 10.5, 5.0 Hz, 2H), 1.65 (dd, J = 15.0, 7.5 Hz, 2H), 1.58 – 1.50 (m, 4H), 1.40 (dd, J = 11.1, 5.6 Hz, 2H), 0.95 (t, J = 7.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.22, 153.99, 140.74, 132.70, 129.24, 128.53, 128.33, 126.13, 125.39, 121.89, 110.01, 104.98, 68.65, 49.67, 37.87, 26.49, 24.61, 24.51, 13.88. HRMS (ESI) m/z calcd for C₂₃H₂₈NO⁺ (M+H)⁺ 334.2165, found 334.2169.

(Z)-1-(2-(thiophen-3-ylmethylene)-2,3-dihydrobenzofuran-3-yl)piperidine




2i, 91%, white solid, mp. = 107-108 °C, (EA/Hex = 15%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 1.7 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.31 – 7.25 (m, 2H), 7.05 – 6.97 (m, 2H), 5.95 (d, J = 1.6 Hz, 1H), 4.96 (s, 1H), 2.73 – 2.62 (m, 2H), 2.53 – 2.40 (m, 2H), 1.54 (d, J = 3.7 Hz, 4H), 1.41 (d, J = 5.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.04, 153.81, 135.95, 129.28, 128.51, 126.18, 125.56, 124.81, 121.97, 109.98, 99.77, 68.23, 49.69, 26.48, 24.48. HRMS (ESI) m/z calcd for C₁₈H₂₀NOS⁺ (M+H)⁺ 298.1260, found 298.1260.

(Z)-1-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)-4-methylpiperidine




2j, 90%, white solid, mp. = 107-108 °C, (EA/Hex = 5%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.5 Hz, 2H), 7.44 – 7.34 (m, 3H), 7.31 – 7.24 (m, 1H), 7.20 (t, J = 7.4 Hz, 1H), 7.07 – 6.99 (m, 2H), 5.85 (d, J = 1.3 Hz, 1H), 5.00 (s, 1H), 2.79 (dd, J = 18.2, 11.7 Hz, 2H), 2.58 (td, J = 11.2, 2.4 Hz, 1H), 2.21 (td, J = 11.1, 2.3 Hz, 1H), 1.66 – 1.54 (m, 3H), 1.36 – 1.23 (m, 2H), 0.89 (d, J = 6.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.12, 154.76, 135.28, 129.29, 128.42, 126.14, 125.33, 122.00, 110.06, 104.97, 68.35, 49.57, 48.47, 34.90, 30.88, 21.96. HRMS (ESI) m/z calcd for C₂₁H₂₄NO⁺ (M+H)⁺ 306.1852, found 306.1859.

(Z)-1-(2-benzylidene-5-(tert-butyl)-2,3-dihydrobenzofuran-3-yl)-4-methylpiperidine




2k, 93%, white solid, mp. = 116-117 °C, (EA/Hex = 5%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.3 Hz, 2H), 7.41 (d, J = 1.9 Hz, 1H), 7.36 (t, J = 7.7 Hz, 2H), 7.29 (dd, J = 8.4, 2.0 Hz, 1H), 7.19 (t, J = 7.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.82 (d, J = 1.4 Hz, 1H), 4.98 (s, 1H), 2.79 (dd, J = 14.2, 11.0 Hz, 2H), 2.56 (td, J = 11.1, 2.3 Hz, 1H), 2.27 – 2.16 (m, 1H), 1.64 – 1.55 (m, 3H), 1.33 (s, 9H), 1.25 (s, 2H), 0.90 (d, J = 6.3 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 155.35, 135.44, 128.36, 126.00, 124.88, 122.94, 109.1, 104.68, 68.60, 49.59, 48.55, 34.92, 34.74, 31.74, 30.91, 29.72. HRMS (ESI) m/z calcd for C₂₅H₃₂NO⁺ (M+H)⁺ 362.2478, found 362.2480.

(Z)-1-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)-4-phenylpiperazine




2l, 97%, white solid, mp. = 118-119 °C, (EA/Hex = 10%, R_f = 0.30). ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, J = 7.5 Hz, 2H), 7.73 (d, J = 7.5 Hz, 2H), 7.45 (d, J = 7.4 Hz, 1H), 7.37 (t, J = 7.7 Hz, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.27 – 7.19 (m, 4H), 7.16 – 6.99 (m, 2H), 7.10 – 7.01 (m, 2H), 6.90 (d, J = 7.9 Hz, 2H), 6.99 – 6.79 (m, 3H), 6.84 (t, J = 7.3 Hz, 1H), 5.90 (d, J = 1.3 Hz, 1H), 5.10 (s, 1H), 3.26 – 3.11 (m, 4H), 2.93 (dt, J = 10.0, 4.9 Hz, 2H), 2.79 – 2.67 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.16, 153.97, 151.43, 135.03, 129.63, 129.08, 128.48, 126.34, 126.21, 124.54, 122.22, 119.79, 116.25, 110.22, 105.53, 67.94, 49.79, 48.38. HRMS (ESI) m/z calcd for C₂₅H₂₅N₂O⁺ (M+H)⁺ 369.1961, found 369.1961.

(Z)-1-(2-benzylidene-6-bromo-2,3-dihydrobenzofuran-3-yl)-4-phenylpiperazine




2m, 99%, white solid, mp. = 125-126 °C, (EA/Hex = 10%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 7.9 Hz, 2H), 7.37 (t, J = 7.6 Hz, 2H), 7.30 (d, J = 7.9 Hz, 1H), 7.27 – 7.21 (m, 5H), 7.18 (d, J = 7.9 Hz, 1H), 6.92 – 6.82 (m, 3H), 5.91 (s, 1H), 5.04 (s, 1H), 3.23 – 3.12 (m, 4H), 2.95 – 2.86 (m, 2H), 2.76 – 2.67 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.83, 153.54, 151.3, 134.58, 129.11, 128.57, 127.22, 126.65, 125.38, 123.83, 122.76, 119.91, 116.30, 113.93, 106.35, 67.46, 49.77, 48.36. HRMS (ESI) m/z calcd for C₂₅H₂₄BrN₂O⁺ (M+H)⁺ 447.1067, found 447.1068.

(Z)-1-(2-benzylidene-5-(tert-butyl)-2,3-dihydrobenzofuran-3-yl)-4-phenylpiperazine




2n, 96%, white solid, mp. = 122-123 °C, (EA/Hex = 5%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.8 Hz, 2H), 7.44 (s, 1H), 7.41 – 7.30 (m, 3H), 7.27 – 7.17 (m, 3H), 6.98 (d, J = 8.4 Hz, 1H), 6.90 (d, J = 8.2 Hz, 2H), 6.84 (t, J = 7.2 Hz, 1H), 5.88 (s, 1H), 5.07 (s, 1H), 3.19 (s, 4H), 2.99 – 2.88 (m, 2H), 2.78 – 2.68 (m, 2H), 1.33 (d, J = 1.4 Hz, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 156.07, 154.61, 151.43, 145.39, 135.21, 129.09, 128.45, 128.30, 126.54, 126.21, 124.08, 122.90, 119.73, 116.13, 109.39, 105.22, 68.22, 49.74, 48.48, 34.50, 31.75. HRMS (ESI) m/z calcd for C₂₉H₃₃N₂O⁺ (M+H)⁺ 425.2587, found 425.2589.

tert-butyl (Z)-4-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)piperazine-1-carboxylate




2o, 93%, white solid, mp. = 124-125 °C, (EA/Hex = 5%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 7.9 Hz, 2H), 7.41 – 7.34 (m, 3H), 7.29 (t, J = 7.8 Hz, 1H), 7.21 (t, J = 7.4 Hz, 1H), 7.08 – 6.99 (m, 2H), 5.85 (s, 1H), 5.03 (s, 1H), 3.41 (s, 4H), 2.59 (d, J = 79.9 Hz, 4H), 1.42 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 158.13, 154.69, 153.85, 134.94, 129.68, 128.47, 126.39, 126.08, 124.41, 122.24, 110.24, 105.55, 79.63, 68.11, 28.42. HRMS (ESI) m/z calcd for C₂₄H₂₉N₂O₃⁺ (M+H)⁺ 393.2173, found 393.2176.

(Z)-4-(2-benzylidene-2,3-dihydrobenzofuran-3-yl)morpholine




2p, 92%, white solid, mp. = 120-121 °C, (EA/Hex = 10%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, J = 7.3 Hz, 2H), 7.43 (d, J = 7.7 Hz, 1H), 7.37 (t, J = 7.7 Hz, 2H), 7.30 (t, J = 7.5 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 7.04 (t, J = 7.6 Hz, 2H), 5.88 (d, J = 1.5 Hz, 1H), 5.00 (s, 1H), 3.74 – 3.64 (m, 4H), 2.82 – 2.72 (m, 2H), 2.61 – 2.52 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.16, 153.79, 134.94, 129.66, 128.45, 126.36, 126.13, 124.37, 122.22, 110.22, 105.57, 68.17, 67.41, 48.73. HRMS (ESI) m/z calcd for C₁₉H₂₀NO₂⁺ (M+H)⁺ 294.1489, found 294.1502.

(Z)-4-(2-benzylidene-6-bromo-2,3-dihydrobenzofuran-3-yl)morpholine




2q, 97%, white solid, mp. = 122-123 °C, (EA/Hex = 10%, R_f = 0.25). ¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 8.0 Hz, 2H), 7.37 (t, J = 7.6 Hz, 2H), 7.28 (d, J = 7.9 Hz, 1H), 7.26 – 7.22 (m, 3H), 7.18 (dd, J = 7.9, 1.2 Hz, 1H), 5.89 (s, 1H), 4.94 (s, 1H), 3.72 – 3.65 (m, 4H), 2.76 – 2.70 (m, 2H), 2.59 – 2.50 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 158.84, 153.35, 134.50, 128.55, 127.13, 126.68, 125.40, 123.66, 122.81, 113.93, 106.44, 67.70, 67.33, 48.70. HRMS (ESI) m/z calcd for C₁₉H₁₉BrNO₂⁺ (M+H)⁺ 372.0594, found 372.0591.

methyl 4-((3-(piperidin-1-yl)benzofuran-2-yl)methyl)benzoate



4a, 95%, white solid, mp. = 130-131 °C, (EA/Hex = 10%, R_f = 0.50). ¹H NMR (400 MHz, CDCl₃) δ 8.03 – 7.93 (m, 2H), 7.70 – 7.63 (m, 1H), 7.41 – 7.31 (m, 3H), 7.23 – 7.12 (m, 2H), 4.20 (s, 2H), 3.89 (s, 3H), 3.16 – 3.07 (m, 4H), 1.74 – 1.58 (m, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 167.05, 153.51, 147.98, 143.97, 130.63, 129.85, 128.61, 128.33, 126.53, 123.42, 121.91, 120.28, 111.54, 53.76, 52.05, 32.51, 26.81, 24.29. HRMS (ESI) m/z calcd for C₂₂H₂₄NO₃⁺ (M+H)⁺ 350.1751, found 350.1759.


1-(2-benzyl-5-bromobenzofuran-3-yl)piperidine



4c, 80%, white solid, mp. = 132-133 °C, (EA/Hex = 10%, R_f = 0.50). ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 1.2 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.26 (d, J = 7.5 Hz, 4H), 7.21 (t, J = 8.6 Hz, 2H), 4.13 (s, 2H), 3.13 – 3.04 (m, 4H), 1.75 – 1.67 (m, 4H), 1.61 – 1.56 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 152.22, 150.57, 138.14, 128.59,


126.51, 126.05, 122.70, 114.95, 112.95, 53.73, 32.52, 26.80, 24.25. HRMS (ESI) m/z calcd for C₂₀H₂₁BrNO⁺ (M+H)⁺ 370.0801, found 370.0801.

1-(2-benzyl-5-methylbenzofuran-3-yl)piperidine




4d, 81%, white solid, mp. = 135-136 °C, (EA/Hex = 10%, R_f = 0.45). ¹H NMR (400 MHz, CDCl₃) δ 7.42 (s, 1H), 7.29 – 7.24 (m, 4H), 7.22 – 7.16 (m, 2H), 6.98 (dd, J = 8.4, 1.3 Hz, 1H), 4.13 (s, 2H), 3.19 – 3.04 (m, 4H), 2.42 (s, 3H), 1.71 (dt, J = 10.8, 5.6 Hz, 4H), 1.59 (dd, J = 11.2, 5.7 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 151.90, 149.14, 138.68, 131.16, 130.04, 128.57, 128.46, 126.77, 126.28, 124.34, 120.02, 111.01, 53.77, 32.50, 26.88, 24.36, 21.41. HRMS (ESI) m/z calcd for C₂₁H₂₄NO⁺ (M+H)⁺ 306.1852, found 306.1860.

1-phenyl-4-(2-(4-propylbenzyl)benzofuran-3-yl)piperazine




4e, 85%, white solid, mp. = 140-141 °C, (EA/Hex = 5%, R_f = 0.20). ¹H NMR (400 MHz, CDCl₃) δ 7.72 – 7.65 (m, 1H), 7.38 (dd, J = 5.3, 2.9 Hz, 1H), 7.33 – 7.26 (m, 2H), 7.21 – 7.15 (m, 4H), 7.10 (d, J = 7.8 Hz, 2H), 7.00 (d, J = 7.8 Hz, 2H), 6.89 (t, J = 7.3 Hz, 1H), 4.14 (d, J = 3.0 Hz, 2H), 3.33 (s, 8H), 2.54 (t, J = 7.6 Hz, 2H), 1.59 (dd, J = 10.5, 4.5 Hz, 2H), 0.95 – 0.88 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 153.51, 151.60, 150.29, 140.88, 135.44, 129.21, 128.73, 128.45, 126.32, 123.41, 122.06, 120.00, 119.98, 116.40, 111.70, 52.43, 50.24, 37.70, 32.00, 24.64, 13.91. HRMS (ESI) m/z calcd for C₂₈H₃₁N₂O⁺ (M+H)⁺ 411.2431, found 411.2437.

I-(2-benzyl-5-bromobenzofuran-3-yl)-4-phenylpiperazine




4f, 87%, white solid, mp. = 139-140 °C, (EA/Hex = 10%, R_f = 0.55). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J = 9.1 Hz, 2H), 7.35 – 7.19 (m, 8H), 6.99 (d, J = 7.9 Hz, 2H), 6.90 (t, J = 7.3 Hz, 1H), 4.16 (s, 2H), 3.31 (s, 8H). ¹³C NMR (100 MHz, CDCl₃) δ 153.85, 151.49, 150.69, 137.87, 129.22, 128.79, 128.65, 126.62, 125.42, 125.32, 120.88, 120.10, 116.77, 116.45, 115.12, 52.39, 50.20, 32.41. HRMS (ESI) m/z calcd for C₂₅H₂₄BrN₂O⁺ (M+H)⁺ 447.1067, found 447.1071.

I-(2-benzyl-5-(tert-butyl)benzofuran-3-yl)-4-phenylpiperazine




4g, 89%, white solid, mp. = 146-148 °C, (EA/Hex = 5%, R_f = 0.50). ¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 1H), 7.36 – 7.30 (m, 3H), 7.28 (d, J = 4.3 Hz, 3H), 7.27 (s, 2H), 7.20 (dd, J = 8.7, 4.3 Hz, 1H), 7.02 (d, J = 8.2 Hz, 2H), 6.90 (t, J = 7.2 Hz, 1H), 4.16 (s, 2H), 3.35 (d, J = 2.4 Hz, 8H), 1.37 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 151.72, 151.57, 150.37, 145.24, 138.37, 129.19, 128.88, 128.58, 126.39, 125.94, 121.36, 120.02, 116.36, 116.02, 110.96, 52.47, 50.26, 32.39, 31.92, 29.71. HRMS (ESI) m/z calcd for C₂₉H₃₃N₂O⁺ (M+H)⁺ 425.2587, found 425.2593.

tert-butyl 4-(2-benzylbenzofuran-3-yl)piperazine-1-carboxylate




4h, 80%, white solid, mp. = 128-129 °C, (EA/Hex = 5%, R_f = 0.55). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, J = 7.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.31 – 7.24 (m, 4H), 7.17 (dt, J = 15.8, 6.9 Hz, 3H), 4.15 (s, 2H), 3.62 – 3.51 (m, 4H), 3.11 (s, 4H), 1.50 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 154.89, 153.47, 150.07, 138.15, 128.82, 128.58, 126.50, 126.16, 123.50, 122.10, 119.88, 111.69, 79.83, 52.20, 32.35, 28.49. HRMS (ESI) m/z calcd for C₂₄H₂₉N₂O₃⁺ (M+H)⁺ 393.2173, found 393.2177.

4-(2-benzyl-5-bromobenzofuran-3-yl)morpholine




4i, 86%, white solid, mp. = 140-141 °C, (EA/Hex = 10%, R_f = 0.5). ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 1.5 Hz, 1H), 7.34 – 7.27 (m, 3H), 7.23 (dd, J = 14.2, 5.9 Hz, 4H), 4.15 (s, 2H), 3.90 – 3.80 (m, 4H), 3.19 – 3.08 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 152.23, 151.72, 137.74, 128.66, 128.53, 128.29, 128.07, 126.66, 126.38, 122.47, 115.26, 113.13, 67.63, 52.50, 32.39. HRMS (ESI) m/z calcd for C₁₉H₁₉BrNO₂⁺ (M+H)⁺ 372.0594, found 372.0600.

4-(2-benzyl-6-bromobenzofuran-3-yl)morpholine




4j, 83%, white solid, mp. = 143-144 °C, (EA/Hex = 10%, R_f = 0.5). ¹H NMR (400 MHz, CDCl₃) δ 7.55 – 7.47 (m, 2H), 7.32 – 7.26 (m, 3H), 7.22 (dd, J = 13.8, 7.0 Hz, 3H), 4.14 (s, 2H), 3.88 – 3.80 (m, 4H), 3.18 – 3.08 (m, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 153.83, 150.90, 137.78, 128.68, 128.51, 126.62, 125.43, 125.16, 120.75, 116.78, 115.14, 67.62, 52.55, 32.33. HRMS (ESI) m/z calcd for C₁₉H₁₉BrNO₂⁺ (M+H)⁺ 372.0594, found 372.0600.

1,4-bis((3-(pyrrolidin-1-yl)benzofuran-2-yl)methyl)benzene




4m, 83%, white solid, mp. = 152-153 °C, (EA/Hex = 20%, R_f = 0.6). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (dd, J = 7.6, 0.9 Hz, 2H), 7.24 (d, J = 7.6 Hz, 2H), 7.13 – 7.01 (m, 8H), 4.08 (s, 4H), 3.27 (t, J = 6.5 Hz, 8H), 1.94 – 1.84 (m, 8H). ¹³C NMR (100 MHz, CDCl₃) δ 153.50, 146.04, 136.90, 128.53, 127.35, 125.93, 123.27, 121.53, 120.19, 111.47, 52.41, 32.50, 25.29. HRMS (ESI) m/z calcd for C₃₂H₃₃N₂O₂⁺ (M+H)⁺ 477.2537, found 477.2542.

2-phenylbenzofuran




6, 95%, white solid, (EA/Hex = 10%, R_f = 0.5). ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 7.5 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.35 (t, J = 7.3 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 7.26 – 7.20 (m, 1H), 7.03 (s, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 155.93, 154.90, 130.49, 129.23, 128.81, 128.57, 124.95, 124.28, 122.95, 120.92, 111.20, 101.32. HRMS (ESI) m/z calcd for C₁₄H₁₁O⁺ (M+H)⁺ 195.0804, found 195.0808.

isoquinoline 2-oxide




8, 93%, white solid, (EA/Hex = 10%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 8.70 (s, 1H), 8.07 (dd, J = 7.1, 1.5 Hz, 1H), 7.72 (d, J = 7.5 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 7.1 Hz, 1H), 7.58 – 7.49 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 136.73, 136.29, 129.61, 129.24, 126.72, 125.11, 124.35. HRMS (ESI) m/z calcd for $\text{C}_9\text{H}_8\text{NO}_+(\text{M}+\text{H})^+$ 146.0600, found 146.0637.

*3-phenyl-1*H*-isochromen-1-one*




10, 92%, white solid, (EA/Hex = 5%, R_f = 0.3). ^1H NMR (400 MHz, CDCl_3) δ 7.83 (dd, J = 10.4, 3.5 Hz, 1H), 7.76 (dd, J = 7.1, 4.1 Hz, 2H), 7.71 – 7.59 (m, 2H), 7.49 – 7.41 (m, 1H), 7.32 (td, J = 7.6, 3.6 Hz, 2H), 7.27 – 7.19 (m, 1H), 6.33 (d, J = 5.5 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.12, 144.59, 140.61, 134.53, 133.10, 130.15, 129.81, 128.80, 128.46, 125.58, 123.39, 119.86, 107.11. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{11}\text{O}_2^+(\text{M}+\text{H})^+$ 223.0754, found 223.0761.

*(Z)-3-(2-methoxybenzylidene)isobenzofuran-1(3*H*)-one*




12, 89%, white solid, (EA/Hex = 5%, R_f = 0.3). ^1H NMR (400 MHz, CDCl_3) δ 8.19 (dd, J = 7.8, 1.4 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 7.25 – 7.18 (m, 1H), 6.96 (t, J = 7.6 Hz, 1H), 6.88 (s, 1H), 6.83 (d, J = 8.3 Hz, 1H), 3.83 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 167.37, 157.05, 144.47, 141.00, 134.38, 131.35, 129.78, 125.43, 123.29, 121.97, 121.09, 120.06, 110.47, 100.85, 55.62. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{13}\text{O}_3^+(\text{M}+\text{H})^+$ 253.0859, found 253.0863.

*3-phenyl-2-(3-(trifluoromethyl)phenyl)isoquinolin-1(2*H*)-one*




16a, 93%, white solid, (EA/Hex = 5%, R_f = 0.3). ^1H NMR (400 MHz, CDCl_3) δ 7.98 (dd, J = 7.3, 4.8 Hz, 1H), 7.88 (dd, J = 7.6, 4.7 Hz, 1H), 7.75 – 7.64 (m, 1H), 7.61 – 7.55 (m, 1H), 7.41 (d, J = 5.6 Hz, 1H), 7.36 – 7.19 (m, 3H), 7.05 – 6.92 (m, 3H), 6.91 – 6.75 (m, 3H). ^{13}C NMR (100MHz, CDCl_3) δ 167.77, 138.52, 136.39, 134.02, 133.17, 132.87, 130.47, 129.48, 129.04, 128.76, 127.46, 127.02, 124.12, 123.99, 123.28, 119.60, 108.05. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{F}_3\text{NO}^+$ ($\text{M}+\text{H}$)⁺ 366.1100, found 366.1109.

2-(4-bromophenyl)-3-phenylisoquinolin-1(2H)-one




16b, 89%, white solid, (EA/Hex = 5%, R_f = 0.3). ^1H NMR (400 MHz, CDCl_3) δ 7.95 – 7.90 (m, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.68 – 7.64 (m, 1H), 7.53 (td, J = 7.5, 0.7 Hz, 1H), 7.41 – 7.36 (m, 1H), 7.21 – 7.14 (m, 2H), 7.04 (t, J = 7.4 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.94 – 6.90 (m, 2H), 6.84 (d, J = 8.5 Hz, 3H). ^{13}C NMR (100MHz, CDCl_3) δ 167.74, 138.54, 133.37, 132.78, 131.23, 130.62, 129.41, 129.18, 128.72, 127.45, 126.95, 123.97, 123.25, 120.34, 119.52, 112.37, 107.85. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{15}\text{BrNO}^+$ ($\text{M}+\text{H}$)⁺ 376.0332, found 376.0340.

(5-methyl-2-phenylfuran-3-yl)(phenyl)methanone




18a, 97%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.83 (d, J = 8.1 Hz, 2H), 7.67-7.63 (m, 2H), 7.49 (dd, J = 8.6, 4.3 Hz, 2H), 7.36 (t, J = 7.6 Hz, 3H), 7.28 (s, 1H), 6.30 (s, 1H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 191.97, 154.51, 151.20, 138.25, 132.63, 130.04, 129.69, 128.59, 128.22, 127.28, 123.75, 121.77, 109.75, 13.42. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{15}\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 263.1067, found 263.1065.

1-(5-methyl-2-phenylfuran-3-yl)ethan-1-one




18b, 93%, light yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 7.4 Hz, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.29 (d, J = 7.4 Hz, 1H), 6.85 (s, 1H), 2.67 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 194.11, 157.93, 151.71, 129.95, 128.77, 127.78, 123.70, 123.27, 105.08, 29.14, 14.52. HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{13}\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 201.0910, found 201.1030.

ethyl 5-methyl-2-phenylfuran-3-carboxylate




18c, 95%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.88 (dd, J = 7.9, 1.2 Hz, 2H), 7.51-7.39 (m, 3H), 6.50 (s, 1H), 4.22 (q, J = 7.1 Hz, 2H), 2.34 (s, 3H), 1.24 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 163.29, 155.30, 129.88, 129.57, 128.61, 128.22, 114.72, 109.17, 60.58, 14.46, 13.37. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{O}_3^+$ ($\text{M}+\text{H}$) $^+$ 231.1016, found 231.1015.

ethyl 2-(4-bromophenyl)-5-methylfuran-3-carboxylate




18d, 91%, light yellow, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 6.44 (s, 1H), 4.28 (q, J = 7.1 Hz, 2H), 2.35 (s, 3H), 1.32 (d, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 163.65, 154.67, 151.38, 131.22, 129.56, 128.95, 123.13, 109.02, 60.48, 14.24, 13.31. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{14}\text{BrO}_3^+$ ($\text{M}+\text{H}$) $^+$ 309.0121, found 309.0129.

5-methyl-2-phenylfuran-3-carbonitrile




18e, 90%, light yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, J = 7.3 Hz, 2H), 7.46 (t, J = 7.4 Hz, 2H), 7.39 (t, J = 7.3 Hz, 1H), 6.26 (s, 1H), 2.38 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.45, 152.48, 129.64, 128.99, 128.39, 125.09, 115.29, 108.96, 92.01, 13.35. HRMS (ESI) m/z calcd for $\text{C}_{12}\text{H}_{10}\text{NO}^+$ ($\text{M}+\text{H}$) $^+$ 184.0757, found 184.0757.

5-methyl-2-(thiophen-2-yl)furan-3-carbonitrile




18f, 84%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.69 (dd, J = 3.7, 0.8 Hz, 1H), 7.41 (dd, J = 5.0, 0.8 Hz, 1H), 7.12 (dd, J = 4.9, 3.8 Hz, 1H), 6.22 (d, J = 0.8 Hz, 1H), 2.36 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.79, 130.41, 128.12, 127.19, 114.72, 108.35, 90.94, 76.71, 13.33. HRMS (ESI) m/z calcd for $\text{C}_{10}\text{H}_8\text{NOS}^+$ ($\text{M}+\text{H}$) $^+$ 190.0321, found 190.0331.

2-methyl-6,7-dihydrobenzofuran-4(5H)-one




18g, 87%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 6.24 (s, 1H), 2.83 (t, J = 6.3 Hz, 2H), 2.49-2.43 (m, 2H), 2.29 (s, 3H), 2.19-2.11 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 194.62, 166.00, 152.60, 122.05, 101.95, 37.57, 23.30, 22.68, 13.32. HRMS (ESI) m/z calcd for $\text{C}_9\text{H}_{11}\text{O}_2^+$ ($\text{M}+\text{H}$)⁺ 151.0754, found 151.0756.

*methyl 5-methyl-2-(*m*-tolyl)furan-3-carboxylate*



18h, 91%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 7.76 (d, J = 7.8 Hz, 2H), 7.31 (t, J = 7.7 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 6.41 (s, 1H), 3.80 (s, 3H), 2.41 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.26, 156.31, 151.03, 137.66, 129.94, 128.60, 127.98, 125.36, 114.04, 108.68, 51.46, 21.49, 13.33. HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{15}\text{O}_3^+$ ($\text{M}+\text{H}$)⁺ 231.1016, found 231.1015.

methyl 2,5-dimethylfuran-3-carboxylate



18i, 89%, yellow solid, (EA/Hex = 5%, R_f = 0.5). ^1H NMR (400 MHz, CDCl_3) δ 6.20 (s, 1H), 3.79 (s, 3H), 2.52 (s, 3H), 2.23 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 164.69, 157.67, 149.91, 113.71, 106.11, 51.07, 13.55, 13.09. HRMS (ESI) m/z calcd for $\text{C}_8\text{H}_{11}\text{O}_3^+$ ($\text{M}+\text{H}$)⁺ 155.0703, found 155.0709.


The known products **2r** and **2s**,^[1] compound **2t**, **2u**, **4b**, **4k** and **4l**,^[2] **14a** and **14b**^[3] were unambiguously authenticated by comparing the obtained ^1H NMR spectroscopic data with those reported in the literature.

[1] N. Wongsa, U. Sommart, T. Ritthiwigrom, A. Yazici, S. Kanokmedhakul, K. Kanokmedhakul, A. C. Willis, S. G. Pyne, *J. Org. Chem.* **2013**, 78, 1138-1148.

[2] G. Purohit, U. C. Rajesh, D. S. Rawat, *ACS Sustainable Chem. Eng.* **2017**, *5*, 6466-6477.


[3] N. Nebra, J. Monot, R. Shaw, B. Martin-Vaca, D. Bourissou, *ACS Catal.* **2013**, *3*, 2930-2934.

1-(benzofuran-2-yl(phenyl)methyl)-4-phenylpiperazine





19, 73%, white solid, mp. = 149-150 °C, (EA/Hex = 5%, R_f = 0.3). ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, J = 7.0 Hz, 2H), 7.52 – 7.43 (m, 2H), 7.38 – 7.31 (m, 2H), 7.30 – 7.15 (m, 5H), 6.89 (d, J = 7.9 Hz, 2H), 6.84 (t, J = 7.3 Hz, 1H), 6.68 (s, 1H), 4.59 (s, 1H), 3.22 (t, J = 4.8 Hz, 4H), 2.65 (d, J = 4.0 Hz, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 157.16, 155.02, 151.31, 138.90, 129.12, 128.59, 128.20, 127.80, 123.91, 122.75, 120.78, 119.70, 116.05, 111.47, 105.16, 69.34, 51.64, 49.25. HRMS (ESI) m/z calcd for C₂₅H₂₅N₂O⁺ (M+H)⁺ 369.1961, found 369.1983.


3-(benzofuran-2-yl(phenyl)methyl)-2-phenyl-1H-indole




21, 51%, white solid, mp. = 151-152 °C, (EA/Hex = 10%, R_f = 0.3). ¹H NMR (400 MHz, CDCl₃) δ 8.13 (s, 1H), 7.54 – 7.48 (m, 2H), 7.47 – 7.40 (m, 3H), 7.40 – 7.33 (m, 4H), 7.27 (dd, J = 5.6, 3.3 Hz, 4H), 7.23 – 7.12 (m, 4H), 6.99 – 6.90 (m, 1H), 6.48 – 6.36 (m, 1H), 5.94 (d, J = 3.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 160.16, 155.04, 141.45, 136.09, 132.58, 128.92, 128.66, 128.39, 128.09, 126.66, 123.50, 122.52, 122.23, 120.61, 119.97, 112.01, 111.24, 110.91, 105.35, 42.47. HRMS (ESI) m/z calcd for C₂₉H₂₂NO⁺ (M+H)⁺ 400.1696, found 400.1698.

NMR Figures of Products








DEPT 135° spectrum of **2a** (in CDCl_3)







¹H NMR spectrum of **2b** (in CDCl₃)





¹³C NMR spectrum of **2b** (in CDCl₃)










¹H NMR spectrum of **2e** (in CDCl₃)




¹³C NMR spectrum of **2e** (in CDCl₃)







¹H NMR spectrum of **2g** (in CDCl₃)




¹³C NMR spectrum of **2g** (in CDCl₃)




^1H NMR spectrum of **2h** (in CDCl_3)





^{13}C NMR spectrum of **2h** (in CDCl_3)





¹H NMR spectrum of **2i** (in CDCl_3)





¹³C NMR spectrum of **2i** (in CDCl_3)






¹H NMR spectrum of **2j** (in CDCl₃)




¹³C NMR spectrum of **2j** (in CDCl₃)












¹H NMR spectrum of **2m** (in CDCl₃)






¹³C NMR spectrum of **2m** (in CDCl₃)
















¹³C NMR spectrum of **4a** (in CDCl₃)




DEPT 135° spectrum of **4a** (in CDCl_3)





¹H NMR spectrum of **4c** (in CDCl₃)




¹³C NMR spectrum of **4c**







DEPT 135 ° spectrum of **4c** (in CDCl_3)










DEPT 135 °spectrum of **4d** (in CDCl_3)










¹H NMR spectrum of **4g** (in CDCl₃)




¹³C NMR spectrum of **4g** (in CDCl₃)





DEPT 135 ° spectrum of **4g** (in CDCl_3)








DEPT 135 °spectrum of **4h** (in CDCl_3)





¹H NMR spectrum of **4i** (in CDCl₃)





¹³C NMR spectrum of **4i** (in CDCl₃)




DEPT 135 ° spectrum of **4i** (in CDCl_3)





¹H NMR spectrum of **4j** (in CDCl₃)





¹³C NMR spectrum of **4j** (in CDCl₃)




DEPT 135 ° spectrum of **4j** (in CDCl_3)






¹H NMR spectrum of **4m** (in CDCl₃)




¹³C NMR spectrum of **4m** (in CDCl₃)









¹H NMR spectrum of **8** (in CDCl₃)






¹³C NMR spectrum of **8** (in CDCl₃)



7.85
7.84
7.82
7.82
7.77
7.76
7.75
7.74
7.68
7.66
7.64
7.64
7.62
7.62
7.46
7.44
7.43
7.34
7.34
7.33
7.32
7.31
7.30
7.25
7.24
7.24
7.23
7.22
6.34
6.32




—167.12
—144.59
—140.61
—134.53
—133.10
—130.15
—129.81
—128.80
—128.46
—125.58
—123.39
—119.86
—107.11










¹³C NMR spectrum of **12** (in CDCl₃)




DEPT 135 °spectrum of **12** (in CDCl_3)







DEPT 135 ° spectrum of **16a** (in CDCl_3)





¹⁹F NMR spectrum of **16a** (in CDCl_3)







¹H NMR spectrum of **16b** (in CDCl₃)






¹³C NMR spectrum of **16b** (in CDCl₃)




































¹H NMR spectrum of **19** (in CDCl₃)



¹³C NMR spectrum of **19** (in CDCl₃)



DEPT 135 ° spectrum of **19** (in CDCl_3)

